- Home
- DTIL vs NGEN Comparison
DTIL vs NGEN Comparison
Compare DTIL & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DTIL | NGEN |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 214.7M | 200.0M |
| IPO Year | 2019 | 2018 |
Fundamental Metrics
Financial Performance| Metric | DTIL | NGEN |
|---|---|---|
| Price | $7.28 | $2.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $45.00 | $18.00 |
| AVG Volume (30 Days) | 260.1K | ★ 552.4K |
| Earning Date | 05-14-2026 | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,070,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.53 | $1.58 |
| 52 Week High | $9.62 | $5.93 |
Technical Indicators
Market Signals| Indicator | DTIL | NGEN |
|---|---|---|
| Relative Strength Index (RSI) | 41.87 | 70.54 |
| Support Level | $7.18 | $1.62 |
| Resistance Level | $7.92 | $4.44 |
| Average True Range (ATR) | 0.46 | 0.14 |
| MACD | -0.10 | 0.05 |
| Stochastic Oscillator | 9.52 | 87.66 |
Price Performance
Historical ComparisonAbout DTIL Precision BioSciences Inc.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
About NGEN NervGen Pharma Corp. Common stock
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.